LEADS TO DEVELOPMENT IS RECRUITING
3rd April 2017
Leads To Development is looking to expand further and wishes to recruit two new outstanding team members.
• The first position is for a Senior Project Manager: Therapeutic preclinical drug development. For more details please visit www.intelliagence.fr.
• The second position is for a Project Manager: Therapeutic drug development. For more details please visit www.intelliagence.fr. The closing date for sending applications for both positions is the 2nd May 2017.
FROM DISCOVERY TO CLINIC: GETTING READY FOR PHASE 1
28th March 2017.
It was great to see so many people present at the conference “From Discovery to Clinic: Getting Ready for Phase 1” hosted by Leads To Development. The presentations outlined all the key aspects of developing a small molecule oral drug from in vivo POC until the end of the first-in-man study. The interaction between presenters and the audience was lively and highly educative. We very much look forward to organising further conferences in the near future.
ADVANCEMENT OF THE CDVAX FP7 PROGRAMME
9th February 2016.
Leads To Development is pleased to announce a number of significant advances in the FP7 programme for the development of an oral vaccine against Clostridium difficile infection. The in vivo pharmacology studies were completed during 2015 and both technical and GMP batches of the vaccine were successfully manufactured. The FP7 consortium has reviewed and validated the preclinical and clinical development programmes following discussions with the German national regulatory authority (Paul-Ehrlich Institute; PEI), in readiness to launch the first-in-man study.
LEADS TO DEVELOPMENT’S NEW EXPANSION
1st August 2015.
Leads To Development is pleased to announce that the team will be further expanded by the appointment of two project managers, Marion and Leila. Marion holds both a PharmD and a PhD and brings her experience in nanoparticle development. Leila has doctoral and post-doctoral experience in oncology and immunology research, and obtained her PhD at the University of Cambridge. Jérôme Quinonéro commented "Our new team members will enable us to provide additional support to our current clients, but also to further expand our client base".
LEADS TO DEVELOPMENT’S EXPANSION
1st January 2014.
Leads To Development announces the appointment of two new project managers to reinforce the team. Emmanuelle joins us from the Rockefeller University in New York where she has been carrying out post-doctoral translational research in neuroscience, under Nobel Prize laureate Prof. Paul Greengard. She is a graduate of the University Pierre et Marie Curie. Nathalie holds a PhD in molecular and cellular toxicology from the University of Konstanz in Germany and has gained R&D experience in France, Germany and Canada.
LAUNCH OF A 6M€ FP7 PROGRAMME
5th Nov 2013.
Leads To Development is delighted to announce their participation in a three-year FP7 funded project to develop an oral vaccine against Clostridium difficile infection. The project is funded by a European Union grant of approximately six million Euros, with the first clinical trials expected to start in S1-2016. The consortium includes UK, French, Belgian and German members.